These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 38904739)

  • 1. Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment.
    Azargoonjahromi A
    Clin Drug Investig; 2024 Jul; 44(7):471-493. PubMed ID: 38904739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
    Kaul I; Sawchak S; Correll CU; Kakar R; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
    Lancet; 2024 Jan; 403(10422):160-170. PubMed ID: 38104575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
    Brannan SK; Sawchak S; Miller AC; Lieberman JA; Paul SM; Breier A
    N Engl J Med; 2021 Feb; 384(8):717-726. PubMed ID: 33626254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
    Kaul I; Sawchak S; Walling DP; Tamminga CA; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
    JAMA Psychiatry; 2024 Aug; 81(8):749-756. PubMed ID: 38691387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results.
    Breier A; Brannan SK; Paul SM; Miller AC
    Psychopharmacology (Berl); 2023 May; 240(5):1191-1198. PubMed ID: 37036495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
    Shekhar A; Potter WZ; Lightfoot J; Lienemann J; Dubé S; Mallinckrodt C; Bymaster FP; McKinzie DL; Felder CC
    Am J Psychiatry; 2008 Aug; 165(8):1033-9. PubMed ID: 18593778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscarinic Receptor Activators as Novel Treatments for Schizophrenia.
    Paul SM; Yohn SE; Brannan SK; Neugebauer NM; Breier A
    Biol Psychiatry; 2024 Oct; 96(8):627-637. PubMed ID: 38537670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study.
    Weiden PJ; Breier A; Kavanagh S; Miller AC; Brannan SK; Paul SM
    J Clin Psychiatry; 2022 May; 83(3):. PubMed ID: 35552528
    [No Abstract]   [Full Text] [Related]  

  • 9. Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal.
    Dean B
    Expert Opin Investig Drugs; 2023; 32(12):1113-1121. PubMed ID: 37994870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
    Mirza NR; Peters D; Sparks RG
    CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M
    Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H
    Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study.
    Sauder C; Allen LA; Baker E; Miller AC; Paul SM; Brannan SK
    Transl Psychiatry; 2022 Nov; 12(1):491. PubMed ID: 36414626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia.
    Correll CU; Angelov AS; Miller AC; Weiden PJ; Brannan SK
    Schizophrenia (Heidelb); 2022 Dec; 8(1):109. PubMed ID: 36463237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review.
    Leber A; Ramachandra R; Ceban F; Kwan ATH; Rhee TG; Wu J; Cao B; Jawad MY; Teopiz KM; Ho R; Le GH; Ramachandra D; McIntyre RS
    Expert Opin Pharmacother; 2024 Mar; 25(4):467-476. PubMed ID: 38515004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
    Andersen MB; Fink-Jensen A; Peacock L; Gerlach J; Bymaster F; Lundbaek JA; Werge T
    Neuropsychopharmacology; 2003 Jun; 28(6):1168-75. PubMed ID: 12700711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classics in Chemical Neuroscience: Xanomeline.
    Bender AM; Jones CK; Lindsley CW
    ACS Chem Neurosci; 2017 Mar; 8(3):435-443. PubMed ID: 28141924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.
    Medina A; Bodick N; Goldberger AL; Mac Mahon M; Lipsitz LA
    Hypertension; 1997 Mar; 29(3):828-34. PubMed ID: 9052903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Muscarinic M1 and M4 receptors: Hypothesis driven drug development for schizophrenia.
    Dean B; Scarr E
    Psychiatry Res; 2020 Jun; 288():112989. PubMed ID: 32315882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
    Bodick NC; Offen WW; Shannon HE; Satterwhite J; Lucas R; van Lier R; Paul SM
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S16-22. PubMed ID: 9339268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.